• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Pulmonary Circulation >Intravenous Iron Therapy in Patients with Idiopathic Pulmonary Arterial Hypertension and Iron Deficiency:
【24h】

Intravenous Iron Therapy in Patients with Idiopathic Pulmonary Arterial Hypertension and Iron Deficiency:

机译：特发性肺动脉高压和铁缺乏症患者的静脉铁疗法：

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

In patients with idiopathic pulmonary arterial hypertension (iPAH), iron deficiency is common and has been associated with reduced exercise capacity and worse survival. Previous studies have shown beneficial effects of intravenous iron administration. In this study, we investigated the use of intravenous iron therapy in iron-deficient iPAH patients in terms of safety and effects on exercise capacity, and we studied whether altered exercise capacity resulted from changes in right ventricular (RV) function and skeletal muscle oxygen handling. Fifteen patients with iPAH and iron deficiency were included. Patients underwent a 6-minute walk test, cardiopulmonary exercise tests, cardiac magnetic resonance imaging, and a quadriceps muscle biopsy and completed a quality-of-life questionnaire before and 12 weeks after receiving a high dose of intravenous iron. The primary end point, 6-minute walk distance, was not significantly changed after 12 weeks (409 ± 110 m before vs. 428 ± 94 m after; P = 0.07). Secondary end points showed that intravenous iron administration was well tolerated and increased body iron stores in all patients. In addition, exercise endurance time (P 0.001) and aerobic capacity (P 0.001) increased significantly after iron therapy. This coincided with improved oxygen handling in quadriceps muscle cells, although cardiac function at rest and maximal V?o2 were unchanged. Furthermore, iron treatment was associated with improved quality of life (P 0.05). In conclusion, intravenous iron therapy in iron-deficient iPAH patients improves exercise endurance capacity. This could not be explained by improved RV function; however, increased quadriceps muscle oxygen handling may play a role. (Trial registration: ClinicalTrials.gov identifier NCT01288651)
机译：在患有特发性肺动脉高压（iPAH）的患者中，铁缺乏症很普遍，并且与运动能力下降和生存期降低有关。先前的研究显示静脉铁剂的有益作用。在这项研究中，我们从安全性和对运动能力的影响方面研究了铁缺乏的iPAH患者中静脉铁疗法的使用，并研究了运动能力的改变是否是由于右心室（RV）功能和骨骼肌氧气处理的变化引起的。包括iPAH和铁缺乏症的15例患者。患者接受了6分钟的步行测试，心肺运动测试，心脏磁共振成像和股四头肌活检，并在接受大剂量静脉铁剂之前和之后12周完成了生活质量调查表。 12周后的主要终点（步行6分钟）没有明显变化（前409±110 m与后428±94 m; P = 0.07）。次要终点显示，所有患者静脉铁剂的耐受性良好，体内铁储备增加。此外，铁疗法后，运动耐力时间（P <0.001）和有氧运动能力（P <0.001）显着增加。尽管静息状态下的心脏功能和最大V？o2保持不变，但是这与股四头肌细胞中的氧气处理得到了改善。此外，铁治疗与生活质量改善相关（P <0.05）。总之，对铁缺乏的iPAH患者进行静脉铁疗法可提高运动耐力。 RV功能的改善无法解释这一点。但是，增加股四头肌肌肉的氧气处理量可能会起作用。 （试验注册：ClinicalTrials.gov标识符NCT01288651）

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号